| Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria C Duvoux, F Roudot–Thoraval, T Decaens, F Pessione, H Badran, ... Gastroenterology 143 (4), 986-994. e3, 2012 | 915 | 2012 |
| Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study PJ Johnson, S Qin, JW Park, RTP Poon, JL Raoul, PA Philip, CH Hsu, ... Journal of clinical oncology 31 (28), 3517-3524, 2013 | 832 | 2013 |
| NASH limits anti-tumour surveillance in immunotherapy-treated HCC D Pfister, NG Núñez, R Pinyol, O Govaere, M Pinter, M Szydlowska, ... Nature 592 (7854), 450-456, 2021 | 794 | 2021 |
| Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study JM Llovet, T Decaens, JL Raoul, E Boucher, M Kudo, C Chang, YK Kang, ... Journal of Clinical Oncology 31 (28), 3509-3516, 2013 | 655 | 2013 |
| Apc tumor suppressor gene is the “zonation-keeper” of mouse liver S Benhamouche, T Decaens, C Godard, R Chambrey, DS Rickman, ... Developmental cell 10 (6), 759-770, 2006 | 620 | 2006 |
| Liver-targeted disruption of Apc in mice activates β-catenin signaling and leads to hepatocellular carcinomas S Colnot, T Decaens, M Niwa-Kawakita, C Godard, G Hamard, A Kahn, ... Proceedings of the National Academy of Sciences 101 (49), 17216-17221, 2004 | 400 | 2004 |
| A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection JC Nault, A De Reyniès, A Villanueva, J Calderaro, S Rebouissou, ... Gastroenterology 145 (1), 176-187, 2013 | 346 | 2013 |
| Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study L Rimassa, E Assenat, M Peck-Radosavljevic, M Pracht, V Zagonel, ... The Lancet Oncology 19 (5), 682-693, 2018 | 344 | 2018 |
| Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends MS Matter, T Decaens, JB Andersen, SS Thorgeirsson Journal of hepatology 60 (4), 855-865, 2014 | 317 | 2014 |
| Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation D Cherqui, A Laurent, N Mocellin, C Tayar, A Luciani, JT Van Nhieu, ... Annals of Surgery 250 (5), 738-746, 2009 | 298 | 2009 |
| Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma T Decaens, F Roudot‐Thoraval, S Bresson‐Hadni, C Meyer, ... Liver Transplantation 11 (7), 767-775, 2005 | 269 | 2005 |
| Impact of UCSF criteria according to pre‐and post‐OLT tumor features: analysis of 479 patients listed for HCC with a short waiting time T Decaens, F Roudot‐Thoraval, S Hadni‐Bresson, C Meyer, ... Liver Transplantation 12 (12), 1761-1769, 2006 | 216 | 2006 |
| Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC R Lencioni, R Montal, F Torres, JW Park, T Decaens, JL Raoul, M Kudo, ... Journal of hepatology 66 (6), 1166-1172, 2017 | 207 | 2017 |
| Macrotrabecular‐massive hepatocellular carcinoma: a distinctive histological subtype with clinical relevance M Ziol, N Poté, G Amaddeo, A Laurent, JC Nault, F Oberti, C Costentin, ... Hepatology 68 (1), 103-112, 2018 | 191 | 2018 |
| Stabilization of β‐catenin affects mouse embryonic liver growth and hepatoblast fate T Decaens, C Godard, A De Reyniès, DS Rickman, F Tronche, JP Couty, ... Hepatology 47 (1), 247-258, 2008 | 185 | 2008 |
| Liver resection for hepatocellular carcinoma in 313 Western patients: tumor biology and underlying liver rather than tumor size drive prognosis MD Kluger, JA Salceda, A Laurent, C Tayar, C Duvoux, T Decaens, ... Journal of hepatology 62 (5), 1131-1140, 2015 | 122 | 2015 |
| Intravoxel incoherent motion (IVIM) MR imaging of colorectal liver metastases: are we only looking at tumor necrosis? M Chiaradia, L Baranes, JT Van Nhieu, A Vignaud, A Laurent, T Decaens, ... Journal of Magnetic Resonance Imaging 39 (2), 317-325, 2014 | 103 | 2014 |
| Predictive factors for response to PD-1/PD-L1 checkpoint inhibition in the field of hepatocellular carcinoma: current status and challenges Z Macek Jilkova, C Aspord, T Decaens Cancers 11 (10), 1554, 2019 | 95 | 2019 |
| Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): Global OPTIMIS final analysis. M Peck-Radosavljevic, M Kudo, JL Raoul, HC Lee, T Decaens, J Heo, ... Journal of Clinical Oncology 36 (15_suppl), 4018-4018, 2018 | 92 | 2018 |
| Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients T Decaens, F Roudot-Thoraval, S Bresson-Hadni, C Meyer, J Gugenheim, ... World Journal of Gastroenterology: WJG 12 (45), 7319, 2006 | 89 | 2006 |
